Home Blog Page 875

SweetNight Launches CoolNest® Hybrid Mattress, Delivering Cooler Nights and Better Sleep for Modern Households

WILMINGTON, Del., April 1, 2026 /PRNewswire/ — SweetNight, a modern sleep brand committed to making intelligent sleep solutions accessible to everyday families, today announced the launch of the CoolNest® Hybrid Mattress. As the second flagship model in the CoolNest® Collection, the mattress combines advanced thermoregulation with a responsive hybrid support system and a comfort top layer to address the needs of hot sleepers. This launch reinforces SweetNight’s focus on user-centric design, providing an optimized balance of temperature control and ergonomic support for families seeking high-quality rest at an accessible price point.

SweetNight CoolNest® Hybrid Mattress
SweetNight CoolNest® Hybrid Mattress

Engineered for Cooler Sleep All Night Long

The CoolNest® Hybrid Mattress is built around the CoolNest® System, a multi-layer cooling architecture designed for high-performance temperature regulation. At the surface, a cool‑to‑the‑touch ice silk cover, featuring over 10,000 micro‑pores per square centimeter, helps rapidly dissipate body heat and deliver an instant cooling sensation.

Beneath the surface, adaptive temperature‑regulation foams absorb and release heat as temperatures shift, helping maintain a stable sleep environment through out the night. Perforated foam layer, combined with a ventilated spring base, enhances airflow and heat buildup.

Reducing Sleep Disruptions with Motion Isolation and Temperature Stability

Recognizing that both temperature consistency and motion control are critical to uninterrupted sleep, the CoolNest® Hybrid integrates a dual-function hybrid design.

Individually pocketed Dynamic Coil™ springs respond independently to movement, helping minimize motion transfer between partners—making it an ideal choice for couples. At the same time, continuous airflow and efficient heat dissipation reduce the likelihood of nighttime overheating, a common cause of sleep disruption.

Ergonomic Support for Improved Sleep Quality

The hybrid support system combines cushioning foams with responsive coils to deliver a balance of comfort and structural support, making it well-suited for sleepers seeking relief from back discomfort.

Zoned coil configurations provide targeted support to promote proper spinal alignment.  Engineered for versatility, the mattress provides deep pressure relief for the shoulders and hips—essential for side sleepers—while maintaining the firm mid-section support required for healthy back sleeping. Reinforced edge support increases usable surface area and stability, offering consistent support across the entire mattress.

Designed for Couples and Versatile Sleep Styles

The DuoSense™ pillow top adds a plush, inviting surface while preserving the underlying support of the hybrid system. This combination of softness and stability accommodates a wide range of sleep preferences, making it especially suitable for couples with differing comfort needs.

Whether sleeping on the back, side, or in combination positions, the responsive design adapts to different body types and movement patterns, delivering consistent comfort throughout the night.

Designed to meet the needs of hot sleepers, busy households, and anyone seeking durable, high‑performance comfort, the CoolNest® Hybrid delivers effective cooling, reduced sleep disruptions, and enhanced overall sleep quality—at a price point designed for everyday accessibility.

Each mattress is backed by a 10-year warranty and includes free shipping, a 100-night home trial, and HSA/FSA eligibility for added convenience and peace of mind.

The CoolNest® Hybrid is now available nationwide at SweetNight Online, with pricing ranging from $399.99 to $799.99.

About SweetNight

SweetNight is a modern sleep brand dedicated to making high-quality, intelligent sleep solutions accessible to everyday families. The company addresses the biggest challenges in smart sleep by delivering technology that is simple, intuitive, and fairly priced. Its mission is to become the world’s leading Self‑Adjusting Sleep Wellness Partner, bringing thoughtful, health‑focused innovation to households everywhere.

Watertech China 2026: The Mandatory Global Hub for Water Innovation and Industrial Transformation

SHANGHAI, April 1, 2026 /PRNewswire/ — WATERTECH CHINA 2026, the landmark 18th edition of the premier platform for process, drinking, and wastewater solutions, will take place from June 9–11, 2026, at the National Exhibition and Convention Center (Shanghai). Co-organized by Herui Group and Informa Markets, the event serves as a critical hub for water treatment technologies, digital management, and sustainable infrastructure.

WATERTECH CHINA 2026: 18th Shanghai International Water Show, June 9-11, at NECC Shanghai
WATERTECH CHINA 2026: 18th Shanghai International Water Show, June 9-11, at NECC Shanghai

Unprecedented Scale and Coverage

The 2026 edition will expand to a massive 180,000 sqm, hosting over 2,500 exhibitors and attracting more than 100,000 professional visitors from 175 countries and regions. Covering the entire water value chain, the exhibition serves 28 end-user industries—from municipal infrastructure to industrial manufacturing—acting as a high-efficiency B2B gateway for global procurement and strategic partnerships.

Leading the “Water 4.0” Revolution

A major highlight is the focus on digital intelligence. The Digital Water Innovation Summit will gather experts to explore AI, IoT, big data, and digital twin technology. Key focus areas include:

  • Smart Monitoring: AI-driven analytics and 5G integration for operational intelligence.
  • Sustainable Infrastructure: Innovations in smart metering and leak detection to reduce environmental impact.
  • Global Export Pathways: Dedicated sessions on international cooperation for intelligent water solutions.

Specialized Industry Zones

The exhibition features targeted zones designed to address pressing global resource challenges:

  • Industrial Water & Zero-Liquid Discharge (ZLD): Advanced membrane technologies and recycling solutions for high-pollution industries.
  • Municipal Drinking Water: Purification, chemical dosing, and health-focused safety technologies.
  • Seawater Desalination: Energy-efficient systems for water-scarce regions.
  • Smart Pipe Networks: High-precision monitoring to optimize network performance and reduce water loss.

Strategic Global Matchmaking

To maximize business impact, the international matchmaking program will connect over 500 leading brands with 10,000 targeted international buyers. To facilitate global participation, the organizers provide comprehensive support, including invitation letters and visa assistance for eligible overseas attendees.

Call to Action

As water management continues to play an increasingly important role in public health, industrial development and sustainability, WATERTECH CHINA 2026 will offer a platform for industry professionals to discover new solutions, exchange insights and build international partnerships. Pre-registration is now open for visitors seeking to connect with the global water community in Shanghai.

Smartee Introduces Material and Trimline Selection Features to Enhance Aligner Customization

SHANGHAI, April 1, 2026 /PRNewswire/ — Smartee Denti-Technology today announced the addition of Material Choice and Trimline Selection features to its digital case management system SmarteeCheck. Available immediately at the case approval stage, these updates provide clinicians with greater flexibility to further customize treatment plans based on personal preferences and dental condition of individual patients.

Material Choice: Balancing Precision and Comfort

Material Choice
Material Choice

Clinicians can now select between Softer and Standard dental sheets when approving a case. This dual-option approach addresses the advanced clinical understanding that different phases of tooth movement require different mechanical properties.

Smartee’s Softer material is suited for treatment stages where patient comfort and initial compliance are priorities, while the Standard material provides the sustained force expression needed for robust control. This functionality allows clinicians to select the appropriate material for each treatment phase without having to switch aligner systems.

Trimline Selection: Evidence from Industry Studies

Trimline Selection
Trimline Selection

The update also allows clinicians to choose from three distinct trimline styles at case approval: Classic Scalloped, Scalloped Extended, and Straight.

This feature aligns with recent clinical studies on aligner biomechanics and aesthetics. A systematic review published in BMC Oral Health noted that trimline design influences orthodontic tooth movement efficacy by affecting force delivery and aligner retention. Additionally, an eye-tracking study in the American Journal of Orthodontics and Dentofacial Orthopedics (AJODO) confirmed that different trimline designs impact how aligners are visually perceived.

To meet diverse clinical requirements, the system offers:

  • Classic Scalloped Trimline: Precisely conforms to the gingival margin for improved aesthetics and comfort.
  • Scalloped Extended Trimline: Extends beyond the margin to enlarge the surface area in the maxillary posterior buccal region for enhanced retention.
  • Straight Trimline: A straight horizontal trimming at the gingival zenith, delivering maximum retention force.

Clinical Flexibility
While some clear aligner systems offer a single standard trimline, Smartee’s update enables doctors to easily toggle between three distinct styles at case approval. This supports personalized treatment planning by allowing orthodontists to balance retention, force control, and gingival aesthetics according to each patient’s specific clinical profile.

Availability
The Material Choice and Trimline Selection features are available globally starting March 31, 2026, for all new case approvals through Smartee’s digital case management system.

GREATER DES MOINES PARTNERSHIP UNVEILS 2026 FEDERAL POLICY AGENDA

Priorities Advance Infrastructure, Workforce and Regional Competitiveness

GREATER DES MOINES, Iowa, April 1, 2026 /PRNewswire/ — The Greater Des Moines Partnership has unveiled its 2026 Federal Policy Agenda, outlining key priorities to advance economic growth, talent development and national competitiveness across the Greater Des Moines region and the state of Iowa.

Developed by The Partnership’s Government Policy Council — representing more than 7,200 Regional Chamber Members and over 400 Investors — and approved by its Board of Directors, the agenda reflects a unified regional approach. It brings together business and community leaders to advocate with one voice on priorities that support long-term growth.

As Greater Des Moines competes nationally for talent and investment, the agenda prioritizes policies that strengthen infrastructure, support workforce development and expand housing opportunities.

The Partnership’s 2026 Federal Policy Agenda focuses on the following priorities:

Regional Transportation
The Partnership supports investment in regional transportation projects that safely and efficiently move goods and people, advance economic growth and support job creation, including the Des Moines Airport Terminal Project, interstate designation of Highway 5/65 and expansion of the Ankeny Regional Airport.

Permitting Reform
The Partnership supports modernizing and improving our nation’s permitting process to expedite critical infrastructure projects and promote economic growth.

Workforce Funding and Programs
Strong workforce impacts every industry and area of the state. The Partnership supports investing in our nation’s workforce through the expansion of apprenticeships, accessible childcare and employer incentives to encourage workforce training and upskilling to help retain employees.

Housing
The Partnership supports the expansion of housing options through funding and policies that encourage communities and employers to invest in new and existing housing.

The Agenda also outlines additional priorities related to economic growth, energy, infrastructure, immigration, health care, education and community development — reflecting the broad policy landscape that supports business success and quality of life in Greater Des Moines.

“This agenda reflects the priorities we hear directly from our Investors and Regional Chamber Members from across Greater Des Moines and the policies needed to sustain growth and competitiveness,” said David Stark, Chair of The Partnership’s Government Policy Council and Chief of Government Affairs and Philanthropy at UnityPoint Health. “By aligning around shared priorities, we are able to advocate more effectively for investments that strengthen our workforce, infrastructure and economy.”

“Our Federal Policy Agenda provides a clear framework for engaging with federal partners and advancing policies aligned with the region’s long-term growth,” said Laura Book, Director of Government Relations and Public Policy at The Partnership. “Through ongoing collaboration with public, private and nonprofit leaders, we are able to bring forward priorities that support businesses, communities and future opportunities across Greater Des Moines.”

The Partnership’s team works year-round to connect regional leaders with policymakers and advance policies that support economic growth, business prosperity and talent development.

The Agenda will be advanced through The Partnership’s annual Washington, D.C. fly-in trip (DMDC) June 3-5, where regional business and community leaders meet directly with Iowa’s congressional delegation and federal officials to advocate for these priorities and strengthen relationships that support long-term growth.

View the full 2026 Federal Policy Agenda and register to attend DMDC by visiting DSMpartnership.com.

About the Greater Des Moines Partnership
The Greater Des Moines Partnership is the largest regional business, economic development and talent development organization in Iowa and the second-largest regional chamber of commerce in the country, serving multiple counties in Greater Des Moines. Together with more than 400 Investors and an Affiliate Chamber of Commerce network of more than 7,200 Regional Chamber Members, The Partnership helps businesses grow and advances quality of life in Greater Des Moines with one voice, one mission and as one region, contributing to a vibrant regional economy. Learn more at DSMpartnership.com.

Contact:
Metinka Slater
mslater@DSMpartnership.com
(515) 216-3989
Learn More About DSM USA

Xinhua Silk Road: Xianyang Fu Tea delegation visits embassies of five countries in Beijing to promote Chinese tea culture

BEIJING, April 1, 2026 /PRNewswire/ — A delegation from Xianyang City, northwest China’s Shaanxi Province, visited the embassies of Pakistan, Peru, Morocco, Türkiye and Fiji in Beijing from March 16 to 19, promoting Xianyang Fu Tea , a kind of Chinese dark tea with over 600 years of history, as part of efforts to expand the tea’s international presence.

The delegation was led by Shi Yaodong, vice chairman of the Xianyang Municipal Committee of the Chinese People’s Political Consultative Conference. He held talks with senior diplomatic representatives from five countries in four days.

Fu Tea is produced in Jingyang County of Xianyang, and is distinguished by a naturally occurring golden fungus called “Jin Hua” (Eurotium cristatum). The fungus, rich in amino acids, vitamins and trace elements, develops inside compressed tea bricks under specific conditions.

The tea’s production technique was inscribed on China’s national intangible cultural heritage list in 2021 and on the UNESCO Representative List of the Intangible Cultural Heritage of Humanity in 2022.

Xianyang Fu Tea currently comprises 65 products across five categories, with an annual production capacity exceeding 30,000 tonnes and a total output value of over 3 billion yuan. The tea has been exported to more than 40 countries, with an assessed brand value of 6.662 billion yuan.

During the visits, each country’s representative highlighted existing connections to Chinese tea culture.

Morocco’s Ambassador Abdelkader El Ansari noted that Morocco is one of the world’s largest importers of Chinese green tea. Türkiye’s Ambassador Selçuk Ünal pointed to tea as a key link along the ancient Silk Road. Pakistan’s Economic Minister Aslam Chaudhary drew parallels between Fu Tea and traditional teas from Pakistan’s northern regions. Peru’s counsellor Jorge García highlighted the country’s large Peruvian Chinese as a foundation for cultural and trade links. Fiji’s Ambassador Robert Lee said the country’s climate and soil may be suitable for growing Chinese tea.

“Tea is a symbol of peace, friendship and openness,” Shi said. “We hope Fu Tea can serve as a bridge between Xianyang and people around the world.”

Original link: https://en.imsilkroad.com/p/349989.html

Baidu’s Apollo Go Commences Fully Driverless Commercial Ride-Hailing in Dubai, Partners with Dubai Taxi Company

  • Apollo Go launches a fully driverless commercial ride-hailing service in Dubai via the Apollo Go app, marking the platform’s first international app deployment.
  • Collaboration with Dubai Taxi Company (DTC) powers Apollo Go’s autonomous mobility expansion in the emirate.

DUBAI, UAE, April 1, 2026 /PRNewswire/ — Baidu Inc. (NASDAQ: BIDU and HKEX: 9888) today announced that its autonomous ride-hailing platform, Apollo Go, in partnership with the Roads and Transport Authority (RTA), has launched a fully driverless commercial ride-hailing service in Dubai via the Apollo Go app, marking the platform’s first international app deployment and a major milestone in the region. This comes alongside Apollo Go’s strategic collaboration with Dubai Taxi Company (DTC), the emirate’s leading mobility service provider, bringing strong local operational expertise to support the service.

The Apollo Go app is now available in Dubai, allowing residents and visitors to hail fully driverless rides. This launch represents a significant step forward in Apollo Go’s plan — announced in March 2025 — to deploy a fleet of more than 1,000 autonomous vehicles in Dubai over the next few years. The collaboration with DTC further strengthens local operations and underscores the commercialization of fully autonomous mobility in the emirate.

The Apollo Go app, now open to public users
The Apollo Go app, now open to public users

Nan Yang, Vice President of Baidu and General Manager of Overseas Business Unit, Intelligent Driving Group, with Mansoor Rahma Alfalasi, Group CEO, DTC
Nan Yang, Vice President of Baidu and General Manager of Overseas Business Unit, Intelligent Driving Group, with Mansoor Rahma Alfalasi, Group CEO, DTC

“Our partnership with DTC represents a new chapter for autonomous mobility in Dubai. By combining our cutting-edge technology with DTC’s local expertise, and through the launch of the Apollo Go app, our first international app deployment, we are creating a safe, efficient and scalable ride-hailing service that sets a new standard for the region. We are proud to contribute to Dubai‘s vision for smart, future-ready transportation,” said Nan Yang, Vice President of Baidu and General Manager of Overseas Business Unit, Intelligent Driving Group.

Mansoor Rahma Alfalasi, Group CEO, DTC, said, “Dubai Taxi Company is proud and excited to be among the first entities to roll out the operations of driverless taxis in Dubai, marking a significant milestone in advancing the emirate’s vision for smart and sustainable mobility. This initiative is in line with DTC’s innovation-driven strategy and its commitment to delivering future-ready services that elevate the customer experience. We are grateful to our strategic partner, the Roads and Transport Authority (RTA), for their unwavering support and the development of a comprehensive infrastructure that enables the seamless deployment of driverless taxis, aligned with the ambition of transforming 25% of all transportation trips into smart and driverless journeys by 2030.”

“We are equally proud to partner with Baidu Inc. to bring this future-forward technology to life, combining global innovation with Dubai‘s pioneering spirit. The successful trials conducted over the past few months have demonstrated the vehicles’ readiness, particularly in terms of safety, reliability, and operational efficiency, reinforcing our confidence in scaling this initiative,” he added.

This commercial launch follows a key milestone earlier this year. In January 2026, Apollo Go received Dubai‘s first-ever driverless testing permit for fully autonomous vehicles without a safety driver. This regulatory approval enables Baidu to operate fully autonomous ride-hailing services in Dubai in the first quarter of 2026, positioning the city as a strategic hub for autonomous mobility innovation. Also in January 2026, Baidu inaugurated the Apollo Go Park in Dubai, which serves as the company’s first overseas operations and management hub, supporting plans for a fleet of over 1,000 autonomous vehicles in the coming years.

Dubai marks a key strategic hub in Apollo Go’s growing global network, as it continues to expand its footprint worldwide. As of February 2026, Apollo Go has completed over 20 million rides worldwide, with weekly rides peaking at more than 300,000 during Q4 2025. Its fleets have accumulated over 300 million autonomous kilometers, including more than 190 million kilometers of fully driverless operations, with an outstanding safety record.

About Baidu

Founded in 2000, Baidu’s mission is to make the complicated world simpler through technology. Baidu is a leading AI company with strong internet foundation, trading on the NASDAQ under “BIDU” and HKEX under “9888.” One Baidu ADS represents eight Class A ordinary shares.

About DTC

DTC was recognised as a public joint stock company under Law No. (21) of 2023. The Company is a leading provider of comprehensive mobility solutions in Dubai, operating a fleet of more than 11,000 vehicles, including more than 6,200 taxis. DTC was established in 1994 to operate a fleet of taxis and has since expanded to offer an extensive range of integrated mobility solutions across four key business lines: taxis, VIP limousines, buses and last mile delivery bike services. DTC is the number one taxi operator by fleet size in Dubai with approximately 45% market share. In 2025, the Company’s taxis and limousines completed 53 million trips.

Media Contact
intlcomm@baidu.com

Bambusa Therapeutics Presented Positive Results from the Phase 1 Multiple Ascending Dose Trial of BBT001 at the 2026 American Academy of Dermatology (AAD) Annual Meeting

– Bambusa’s lead product candidate, BBT001 is a next-generation long-acting bispecific antibody targeting two clinically and commercially validated targets, IL-4Rα and IL-31 for the treatment of atopic dermatitis (AD) and other type 2 inflammatory skin diseases –

– BBT001 achieved rapid, deep, and sustained effects on key biomarkers of interest in AD for at least 12 weeks, including reduction of TARC and inhibition of pSTAT6 –

– BBT001 was well tolerated across all doses in both the single- and multiple-ascending dose cohorts of the Phase 1 trial –

– BBT001 exhibited a consistent half-life of approximately 33 days in Phase 1 trial supporting prolonged maintenance dosing interval compared to currently approved medicines in AD –

– Bambusa plans to disclose data from the ongoing placebo-controlled, 4-week Phase 1b/2a trial of BBT001 in patients with moderate to severe atopic dermatitis in the middle of 2026 –

BOSTON, April 1, 2026 /PRNewswire/ — Bambusa Therapeutics, Inc. (Bambusa Therapeutics), a clinical-stage biotechnology company advancing next-generation bispecific antibodies for immunology and inflammation, today announced it presented data from the multiple ascending dose (MAD) cohorts of the Phase 1 trial evaluating BBT001 in healthy volunteers at the 2026 American Academy of Dermatology Annual Meeting (AAD 2026) in Denver, Colorado.

The AAD 2026 clinical poster of BBT001 titled, “Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BBT001, a Novel Bispecific IL-4Rα/IL-31 Antibody: Results from the Single- and Multiple-Ascending Dose Portions of a Phase 1 Study of Healthy Volunteers and Patients with Atopic Dermatitis” highlighted the following data:

  • % change in Thymus and Activation-Regulated Chemokine (TARC). TARC levels in the blood correlate strongly with disease severity in AD (e.g. Eczema Area and Severity Index [EASI] score).
    • BBT001 demonstrated unprecedented dose-dependent, rapid, deep, and sustained reduction in TARC compared to baseline after multiple doses.
  • % change in phosphorylated STAT6 (pSTAT6). pSTAT6 is a key downstream mediator of type 2 inflammation in atopic dermatitis.
    • BBT001 achieved rapid, complete, and sustained inhibition of pSTAT6 for at least 12 weeks after multiple doses.
  • Pharmacokinetics (PK): BBT001 exhibited prolonged PK with a half-life of approximately 33 days at or above target exposure after multiple doses, consistent with the PK observed in the SAD cohorts.
  • Safety and Tolerability: BBT001 was well-tolerated across all doses in the SAD cohorts (previously presented at EADV 2025) and MAD cohorts with a clean safety profile observed in the trial.
  • Immunogenicity: The incidence of anti-drug antibodies (ADA) was low and showed no apparent impact on safety or PK.

“We were excited to highlight the data from our BBT001 clinical program for the first time at the American Academy of Dermatology Annual Meeting,” said Thang Ho, Ph.D., Chief Scientific Officer at Bambusa Therapeutics. “The Phase 1 MAD data confirm the earlier clinical evidence achieved in the SAD portion of the trial, and further support BBT001’s potential to become a best-in-disease biologic to treat atopic dermatitis. Importantly, these data continue to support the potential for BBT001 to deliver faster onset and improved clinical outcomes for patients with atopic dermatitis compared to currently approved medicines.”

“Following our team’s rapid execution of the BBT001 Phase 1 trial including the presentation of the positive data from all doses and cohorts, we now look forward to disclosing data from our ongoing BBT001 4-week Phase 1b/2a trial in patients with atopic dermatitis in the middle of this year,” said Shanshan Xu, M.D., Ph.D., Founder & Chief Executive Officer of Bambusa Therapeutics. “The possibility to generate our first proof-of-concept clinical data in patients with AD is a significant milestone for Bambusa Therapeutics, and it has the exciting potential to give us the first look of how BBT001 could redefine the standard of care for people with atopic dermatitis in the future.”

BBT001 is currently being evaluated in multiple ongoing Phase 1b/2a trials in patients with moderate to severe AD. The Company expects to disclose data from the ongoing 4-week placebo-controlled trial in the middle of 2026.

About the Phase 1 SAD/MAD trial of BBT001

BBT001-001 is a randomized, placebo-controlled, single- and multiple-ascending-dose study in healthy volunteers and adults with moderate to severe atopic dermatitis. The trial is evaluating safety, tolerability, pharmacokinetics, immunogenicity, pharmacodynamics, and preliminary clinical activity.

About BBT001

BBT001 is Bambusa Therapeutics’ lead clinical program and a first-in-class, multi-targeting, half-life extended bispecific antibody engineered to block both IL-4Rα and IL-31 signaling. By addressing type 2 inflammation and directly targeting the pathways that drive itch, BBT001 is designed to provide faster and more durable relief for patients with atopic dermatitis and other inflammatory skin diseases. The molecule has demonstrated a favorable safety profile and strong pharmacokinetics in healthy volunteers, supporting its advancement into multiple clinical trials in patients, including AD and chronic spontaneous urticaria (CSU).

About Bambusa Therapeutics

Bambusa Therapeutics is a clinical-stage biotechnology company developing a portfolio designed to transform care across a wide spectrum of chronic diseases. Powered by an innovative antibody engineering platform featuring half-life extension and high-concentration subcutaneous delivery, Bambusa’s vision is to deliver transformative medicines for patients across every stage of life — setting a new pace for the next era of I&I therapeutics.

  • BBT001 is a first-in-class half-life-extended bispecific antibody targeting IL-4Rα and IL-31 with best-in-disease potential. It is currently in Phase 1b/2a proof-of-concept development for atopic dermatitis and other type 2 inflammatory skin diseases.

  • BBT002 is a first-in-class half-life-extended bispecific antibody targeting IL-4Rα and IL-5 with platform-in-a-molecule potential. It is currently in Phase 1b proof-of-concept development for type 2 inflammatory disorders including COPD, asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), eosinophilic esophagitis, and food allergy.
  • BBT003 and BBT004 are preclinical programs focused on gastroenterology and rheumatology, respectively.

 

MicroAlgo Announces Substantial Increase of 143.5% in Net Profit for 2025

SHENZHEN, China, April 1, 2026 /PRNewswire/ — MicroAlgo Inc. (NASDAQ: MLGO), (the “Company”), a leading developer and application provider of bespoke central processing algorithms, today announced its financial results for the year ended December 31, 2025.

Financial Highlights 2025

The Company’s net profit for 2025 was RMB 127.56 million (USD 18.15 million), representing a substantial increase of 143.5% compared with the same period of the prior year, demonstrating the Company’s strong profitability.

Diluted earnings per share for 2025 were RMB 14.87 (USD 2.12), compared with RMB 3.99 in 2024, representing an increase of 272.7%.

Total shareholders’ equity more than doubled, reaching RMB 2,321.80 million (USD 330.33 million) as of December 31, 2025, representing an increase of 122.8% from RMB 1,041.93 million at the end of 2024.

Operating Performance

The Company continued to focus on its core central processing algorithm services and is committed to providing high-quality solutions for internet advertising customers. In 2025, the Company achieved operating revenue of RMB 422.05 million (USD 60.05 million), gross profit of RMB 108.82 million (USD 15.48 million), with a gross margin of 25.8%.

Operating expenses decreased significantly by 35.3% year-on-year, mainly due to the successful completion of major algorithm development projects and strict cost control measures. Operating profit amounted to RMB 22.38 million (USD 3.18 million), increase of 11.1% compared with the same period, reflecting continuous improvements in the Company’s operational efficiency and cost management.

Quote from Min Shu, CEO of MicroAlgo:

“2025 is the year when we achieved outstanding results. We have achieved strong growth in net profit while maintaining stable cash flow and ample liquidity. These achievements fully demonstrate the robustness of the company’s core business and our continuous efforts in cost control and operational efficiency improvement. We believe that with a solid financial foundation and clear strategic direction, the company is fully prepared for sustainable growth in the future.”

The information disclosed in this press release does not purport to be complete and is qualified in its entirety by reference to the Company’s annual report on Form 20-F. The annual report, which contains the Company’s audited consolidate statements, can be accessed on the SEC’s website at http://www.sec.gov and on the Company’s investor relations website at http://ir.microalgor.com/.

About MicroAlgo Inc.

MicroAlgo Inc. (the “MicroAlgo”), a Cayman Islands exempted company, is dedicated to the development and application of bespoke central processing algorithms. MicroAlgo provides comprehensive solutions to customers by integrating central processing algorithms with software or hardware, or both, thereby helping them to increase the number of customers, improve end-user satisfaction, achieve direct cost savings, reduce power consumption, and achieve technical goals. The range of MicroAlgo’s services includes algorithm optimization, accelerating computing power without the need for hardware upgrades, lightweight data processing, and data intelligence services. MicroAlgo’s ability to efficiently deliver software and hardware optimization to customers through bespoke central processing algorithms serves as a driving force for MicroAlgo’s long-term development.

Safe Harbor / Forward-Looking Statements

This press release contains statements that may constitute “forward-looking statements.” Forward-looking statements are subject to numerous conditions, many of which are beyond the control of MicroAlgo, including those set forth in the Risk Factors section of MicroAlgo’s periodic reports on Forms 20-F and 6-K filed with the SEC. Copies are available on the SEC’s website, www.sec.gov. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, MicroAlgo’s expectations with respect to future performance and anticipated financial impacts of the business transaction.

MicroAlgo undertakes no obligation to update these statements for revisions or changes after the date of this release, except as may be required by law.